Funds
Hedge funds kicked off 2026 with momentum posting an average return of 0.9% in January, marking a run of 10 consecutive months of positive performance, according to the latest Monthly Hedge Fund report from global hedge fund administrator Citico.
Europe’s high-net-worth investors are once again turning to alternative UCITS funds – liquid hedge fund-style products – drawn by strong returns and the flexibility to access capital quickly, according to a report by Bloomberg.
Brevan Howard’s flagship digital assets fund suffered a sharp reversal in 2025, sliding nearly 30 per cent as a broad sell-off across cryptocurrencies weighed on one of the hedge fund industry’s most prominent players in the space, according to a report by the Financial Times.
Muzinich & Co has launched the Muzinich Global Credit Market Neutral Fund a new strategy that aims to capitalise on mispricing and dislocations in global credit while minimising exposure to broader market movements.
Hedge funds delivered positive performance and attracted fresh capital at the start of 2026, with the SS&C GlobeOp Hedge Fund Performance Index recording a gross return of 1.34% in January, and the SS&C GlobeOp Capital Movement Index, up 0.87% in February.
Singapore sovereign wealth fund GIC has redeemed around $250m from Jain Global, less than two years after backing one of the hedge fund industry’s largest-ever launches, according to a report by The Business Time citing sources familiar with the matter.
Tycho Capital has launched a new UCITS vehicle in partnership with London-based CapeView Capital, the Tycho CapeView European Long Short Fund, which debuted with over $40m in investor commitment and is targeting European equity long-short strategies.
Hedge funds are entering 2026 with strong momentum after delivering double-digit returns last year and exceeding allocator expectations, according to a new survey by Goldman Sachs of pension funds, family offices, funds of funds, and other pools of capital.
Most life sciences and biopharma hedge funds started 2026 on the back foot, giving up ground in January after one of the strongest years on record for the sector with the pull-back coming despite a 2.5% gain in the Nasdaq Biotechnology Index, according to a report buy Institutional Investor.
Leading macro hedge funds, including Rokos Capital Management and Pharo Management, delivered strong gains in January as heightened volatility across global markets created fertile conditions for discretionary traders, according to a report by Bloomberg.
